[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368954-105":59,"doc-detail-368954-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","dual-targeting-of-pd-1pd-l1-and-il-33st2-signalling-pathways-a-promising-approach-in-breast-cancer-immunotherapy","Dual targeting of PD-1/PD-L1 and iL-33/ST2 signalling pathways - a promising approach in breast cancer immunotherapy","","The review examines how dual immune checkpoint and cytokine-pathway interference may improve breast cancer immunotherapy. It addresses limited PD-1/PD-L1 efficacy driven by an immunosuppressive tumour microenvironment (TME). IL-33/ST2 signalling, linked to type 2 inflammation, can promote immune evasion and metastasis, motivating its inhibition. The article synthesizes evidence that IL-33 blockade reprograms the TME to increase cytotoxic T-cell infiltration, countering resistance.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dual-targeting-of-pd-1pd-l1-and-il-33st2-signalling-pathways-a-promising-approach-in-breast-cancer-immunotherapy/368954/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dual-targeting-of-pd-1pd-l1-and-il-33st2-signalling-pathways-a-promising-approach-in-breast-cancer-immunotherapy/368954.png","ImageObject",300,407,{"name":92,"@type":93},"kopisore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-22","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is PD-1/PD-L1 blockade often less effective in breast cancer?","Question",{"text":113,"@type":114},"Its efficacy is frequently limited by the tumour microenvironment (TME), which is complex and immunosuppressive.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What roles does IL-33/ST2 signalling play in breast cancer?",{"text":118,"@type":114},"IL-33/ST2 contributes to type 2 inflammation and is associated with pro-tumoral effects such as immune evasion and metastasis, while also showing context-dependent regulation of immune responses.",{"name":120,"@type":111,"acceptedAnswer":121},"How does the dual-targeting strategy work to overcome treatment resistance?",{"text":122,"@type":114},"Combining PD-1/PD-L1 blockade with IL-33/ST2 inhibition targets two cooperative immune evasion mechanisms, with IL-33/ST2 pathway inhibition reprogramming the TME and enhancing anti-tumour immunity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368954,1790208197,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","AnnAls of Medicine  \n2025, Vol. 57, no. 1, 2593198  \n[https://doi.org/10.1080/07853890.2025.2593198](https://doi.org/10.1080/07853890.2025.2593198)  \nREVIEW ARTICLE     \nDual targeting of PD-1/PD-L1 and iL-33/ST2 signalling pathways: a promising approach in breast cancer immunotherapy  \nMilan Jovanovica,b , Nevena Gajovicc , Miodrag Jocicb,d , Marina Jovanovicc,e , Milena Jurisevicc,f  and Ivan Jovanovicc,g   \nadepartment of Abdominal surgery, Military Medical Academy, Belgrade, serbia; bMedical faculty of the Military Medical, Academy University of defense, Belgrade, serbia; ccenter for Molecular Medicine and stem cell Research, University of Kragujevac, Kragujevac, serbia; dinstitute for Transfusiology and Haemobiology, Military Medical Academy, Belgrade, serbia; edepartment of otorhinolaryngology, University of Kragujevac, Kragujevac, serbia; fdepartment of Pharmacy, University of Kragujevac, Kragujevac, serbia; gdepartment of Medicine, University of east sarajevo, foca, Bosnia and Herzegovina  \nABSTRACT  \nIntroduction: The immune checkpoint axis PD-1/PD-L1 is a cornerstone of cancer immunotherapy. However, its efficacy in breast cancer is often limited by a complex and immunosuppressive tumour microenvironment (TME). The IL-33/ST2 signalling pathway, a key player in type 2 inflammation, is increasingly recognized for its pro-tumoral roles in various cancers, contributing to immune evasion and metastasis. This review explores the synergistic potential of combining PD-1/PD-L1 blockade with IL-33/ST2 inhibition to overcome therapeutic resistance and enhance anti-tumour immunity in breast cancer.  \nMethods: Current literature on the PD-1/PD-L1 and IL-33/ST2 pathways in breast cancer progression was synthesized, focusing on their mechanisms of immune suppression and TME modulation. It examines preclinical and clinical data on the individual and combined therapeutic strategies targeting these pathways.  \nResults: Evidence suggests that IL-33 signalling promotes a suppressive TME by recruiting regulatory T cells, myeloid-derived suppressor cells, and M2 macrophages, which can limit the effectiveness of PD-1/PD-L1 inhibitors. Conversely, blocking the IL-33/ST2 pathway has been shown to reprogram the TME, leading to increased infiltration of cytotoxic T lymphocytes and enhanced anti-tumour responses. Therefore, a dual-targeting approach is proposed to simultaneously disarm these two distinct but cooperative immune evasion mechanisms.  \nConclusion: Dual blockade of PD-1/PD-L1 and IL-33/ST2 signalling pathways represents a novel and promising strategy to enhance the efficacy of immunotherapy in breast cancer. This approach has the potential to revert the immunosuppressive TME, leading to more durable and robust anti-tumour responses. Further research is warranted to validate this hypothesis and translate it into effective clinical trials.  \nKEY MESSAGES  \n• While immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have shown clinical efficacy in triple-negative breast cancer, variable therapeutic responses highlight the need for additional targets and more precise biomarkers.  \n• The IL-33/ST2 signalling pathway plays a complex, dual role in the tumour microenvironment, acting as both a pro-tumorigenic and an anti-tumorigenic regulator of immune responses depending on the context.  \n• Combined immunotherapeutic strategies that simultaneously modulate both the PD-1/PD-L1 and IL-33/ST2 pathways show a synergistic potential to enhance anti-tumour immunity and overcome resistance in breast cancer.  \nIntroduction  \nARTICLE HISTORY  \nReceived 4 August 2025 Accepted 14 November 2025  \nKEYWORDS  \nBreast cancer; PD-1/PD-L1 pathway; IL-33/ST2  \npathway; immunotherapy; combination therapy  \nBreast cancer remains the most frequently diagnosed malignant tumour and the leading cause of cancer-related death in women globally, with 2.3 million new cases and 666,000 deaths reported in 2022,  \nCONTACT Miodrag Jocic  [jocicmiodrag@gmail.com](joc","cbCaicSf7XYZb1w4","https://ap.wps.com/l/cbCaicSf7XYZb1w4","pdf",1079378,18,"English","# Abstract\n# Methods\n# Results\n# Conclusion\n# Key Messages\n# Introduction\n# Article History\n# Keywords","[{\"question\":\"Why is PD-1/PD-L1 blockade often less effective in breast cancer?\",\"answer\":\"Its efficacy is frequently limited by the tumour microenvironment (TME), which is complex and immunosuppressive.\"},{\"question\":\"What roles does IL-33/ST2 signalling play in breast cancer?\",\"answer\":\"IL-33/ST2 contributes to type 2 inflammation and is associated with pro-tumoral effects such as immune evasion and metastasis, while also showing context-dependent regulation of immune responses.\"},{\"question\":\"How does the dual-targeting strategy work to overcome treatment resistance?\",\"answer\":\"Combining PD-1/PD-L1 blockade with IL-33/ST2 inhibition targets two cooperative immune evasion mechanisms, with IL-33/ST2 pathway inhibition reprogramming the TME and enhancing anti-tumour immunity.\"}]","Dual targeting of PD-1/PD-L1 and iL-33/ST2 signalling pathways - a promising approach in breast cancer immunotherapy | PDF",1790179755,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77b136aa405c99b41d934729edecbbba.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0251a8a61378895af407c12bf734ddcd.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4088ec8cced89267038e526cac282337.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e0badc637b3eeaead6dc74df6f3b8a6.webp",980,1306]